Targeting immune evasion in advanced cancer using specific antibodies
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
This study is looking at how some proteins help cancer cells hide from the immune system, and it’s testing new antibodies that could help the immune system fight tumors better, which might lead to improved treatment for patients with advanced cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11132179 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain proteins, MICA and MICB, are used by cancer cells to evade the immune system. By developing antibodies that block the shedding of these proteins, the research aims to enhance the immune response against tumors. The approach involves testing these antibodies in laboratory models and evaluating their effectiveness in a clinical trial for patients with advanced cancer. Patients may benefit from improved anti-tumor immunity and potentially better treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced cancer who may benefit from enhanced immune responses.
Not a fit: Patients with early-stage cancer or those whose cancer does not express MICA/B proteins may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the immune system's ability to fight advanced cancer.
How similar studies have performed: Other research has shown promise in targeting immune evasion mechanisms in cancer, making this approach both innovative and grounded in prior success.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Wucherpfennig, Kai W — Dana-Farber Cancer Inst
- Study coordinator: Wucherpfennig, Kai W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.